Zevra Therapeutics, Inc.

ZVRA • Biotechnology

$12.40

▼ -0.14 (-1.12%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$760.57M

Crecimiento

—

Flujo de caja

1/5

Tendencia

Volatile

Evidencia

Márgenes estables o en mejora · 78.2%Crecimiento positivo de ingresos · 18.9%Múltiplo de ganancias razonable · 5.95Nivel de deuda manejable · 0.41Liquidez saludable · 5.68

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 7 ago 2026, 1:21 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$12.40

Change-1.12%

Shares Out61.34M

Market Cap$760.57M

Enterprise Value$539.00M

52W Range7.16 - 15.04

Beta0.85

P/E13.05

P/S5.59

P/B3.49

P/FCF19.64

EV/Sales3.96

Price$12.40

Change-1.12%

Shares Out61.34M

Market Cap$760.57M

Enterprise Value$539.00M

52W Range7.16 - 15.04

Beta0.85

P/E13.05

P/S5.59

P/B3.49

P/FCF19.64

EV/Sales3.96

EV/EBITDA13.91

EV/FCF13.92

Earnings Yield7.66%

FCF Yield5.09%

Dividend Yield0.00%

Gross Margin84.52%

Oper. Margin-3.98%

Profit Margin78.17%

Debt/Eq0.41

Current Ratio5.68

Quick Ratio5.63

Target$25.75

Target Upside107.66%

Target Median$24.00

Target Range20.00 - 35.00

Volume2.48M

Avg Volume1.74M

EPS Surprise0.12

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

65/100

Fortaleza financiera

Deuda, caja, estabilidad

75/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

83/100

Por qué este puntaje▼

Márgenes estables o en mejora · 78.2%Crecimiento positivo de ingresos · 18.9%Múltiplo de ganancias razonable · 5.95Nivel de deuda manejable · 0.41Liquidez saludable · 5.68

Analyst view

Analyst sentiment and price target

ZVRA

Analyst sentiment

Based on 10 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-07

Bajo

$20.00

Promedio

$25.75

Mediana

$24.00

Alto

$35.00

Resumen de la compañía

IPO: 4/16/2015

Industria: Biotechnology

P/B i: 3.49

Deuda / Patrimonio i: 0.41

Margen operativo: -3.98%

Margen neto: 78.17%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.41

Ratio corriente: 5.68

Ratio rápido: 5.63

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Thompson Rahsaan

Transacción: 06/22/2026

VENTA

Cambio

-34,557

Precio

$12.68

Presentación

06/23/2026

Tipo

VENTA

Thompson Rahsaan

Transacción: 06/21/2026

VENTA

Cambio

-66,667

Precio

Not reported

Presentación

06/23/2026

Tipo

VENTA

Thompson Rahsaan

Transacción: 06/21/2026

COMPRA

Cambio

+66,667

Precio

Not reported

Presentación

06/23/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Thompson Rahsaan	VENTA	-34,557	$12.68	06/22/2026	06/23/2026
Thompson Rahsaan	VENTA	-66,667	Not reported	06/21/2026	06/23/2026
Thompson Rahsaan	COMPRA	+66,667	Not reported	06/21/2026	06/23/2026
Shih Alvin	COMPRA	+30,000	$11.17	06/04/2026	06/18/2026
Anderson Thomas	COMPRA	+30,000	$11.17	06/04/2026	06/18/2026
Calder Douglas W	COMPRA	+30,000	$11.17	06/04/2026	06/18/2026
Watton Corey Michael	COMPRA	+30,000	$11.17	06/04/2026	06/18/2026
Secor Alicia	COMPRA	+30,000	$11.17	06/04/2026	06/18/2026
FAVORITO TAMARA A	COMPRA	+30,000	$11.17	06/04/2026	06/18/2026
Sangiovanni Timothy J.	COMPRA	+20,000	Not reported	05/28/2026	05/29/2026
Sangiovanni Timothy J.	COMPRA	+40,000	$11.40	05/28/2026	05/29/2026
Thompson Rahsaan	VENTA	-1,794	$11.30	05/11/2026	05/13/2026
Bode John B	VENTA	-39,200	$4.89	03/24/2026	03/26/2026
Bode John B	COMPRA	+39,200	$4.97	03/24/2026	03/26/2026
Renz Justin A	OTRO	0	Not reported	03/18/2026	03/19/2026
Renz Justin A	COMPRA	+300,000	$9.55	03/18/2026	03/19/2026
McFarlane Neil F.	VENTA	-14,625	$8.56	02/09/2026	02/10/2026
McFarlane Neil F.	VENTA	-37,500	Not reported	02/07/2026	02/10/2026
McFarlane Neil F.	COMPRA	+37,500	Not reported	02/07/2026	02/10/2026
Schafer Joshua	VENTA	-10,500	$9.19	02/03/2026	02/04/2026

Sobre la compañía

Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.

Fuente - Link

Competidores

AKBA CRVS GOSS KALV NAGE OLMA PRTA RGNX RIGL VTYX

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Zevra Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra's executive leadership team will present at the following investor conferences in New York, NY.

GlobeNewsWire

Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium

BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced the presentation of two posters featuring long-term real-world data on MIPLYFFA® (arimoclomol) for the treatment of Niemann-Pick disease type C (NPC) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium. “These presentations further expand the growing body of evidence supporting the long-term safety and effectiveness of arimoclomol in NPC,” said Caroline Hastings, MD, Professor of Pediatrics, UCSF Benioff Children's Hospital Oakland.

GlobeNewsWire

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 92,200 shares of the Company's common stock (the “Inducement Awards”) to four new employees pursuant to the Company's 2023 Employment Inducement Award Plan. Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee's start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee's continued employment on each vesting date).

GlobeNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

PRNewsWire

Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA

Dimensional Fund Advisors LP boosted its holdings in Zevra Therapeutics, Inc. (NASDAQ: ZVRA) by 259.2% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 554,802 shares of the company's stock after buying an additional 400,336 shares during the quarter. Dimensional Fund Advisors

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-06	0.06	0.18	0.12
2026-03-09	0.0504	1.16	1.1096
2025-11-05	-0.02	-0.01	0.01
2025-08-12	2.19	1.21	-0.98
2025-05-13	-0.21	-0.06	0.15
2025-03-11	-0.39	-0.67	-0.28
2024-11-12	-0.44	-0.69	-0.25
2024-08-13	-0.47	-0.48	-0.01
2024-05-08	-0.49	-0.4	0.09
2024-03-28	-0.2	-0.4	-0.2
2023-11-07	-0.29	-0.4	-0.11
2023-08-14	-0.39	-0.15	0.24